Cambridge Cognition Holdings PLC New product to improve workplace mental health
June 20 2018 - 1:00AM
RNS Non-Regulatory
TIDMCOG
Cambridge Cognition Holdings PLC
20 June 2018
Cambridge Cognition Holdings Plc
('Cambridge Cognition' or the 'Company')
New product to improve workplace mental health
The digital neuroscience company Cambridge Cognition Holdings
plc (AIM: COG), which develops and markets digital solutions to
assess brain health, is pleased to announce a planned new software
product to assess mental health and wellbeing at work, CANTAB
BrainHealth(TM).
Mental health conditions, such as depression, anxiety and
stress, are the leading cause of disability worldwide(1) . In the
workplace, 470 million workdays are lost each year due to poor
mental health in the UK and US alone, costing employers an
estimated $225.8 billion per annum(2) .
The majority of these costs are as result of 'presenteeism', the
loss of productivity in employees affected by a mental health
condition, which will often go unreported until symptoms worsen and
require time away from work.
While there is a growing awareness of the need for mentally fit
workplaces, to date these have focused on education around what
mental illness is and what to do if someone requests help. What has
not been addressed well is how to identify problems before they
affect health and performance.
Launching in H2 2018, CANTAB BrainHealth(TM) is a fast, accurate
and easy-to-use digital health product. Designed for occupational
health professionals, it will measure and monitor mental wellbeing
and cognitive performance in the workplace and help combat the
growing global mental health crisis. The Company expects to work
closely with channel partners, initially in the US and the UK, to
commercialise the product.
Using proprietary cognitive assessment technology, the Company's
new product accurately measures cognition and mood objectively,
identifying signs of an underlying brain health condition
early.
The short assessment instantly reports on the individual's
wellbeing, comparing their performance with expected healthy levels
and providing expert advice from healthcare professionals on ways
to intervene and improve. Follow-up assessments can then monitor
the individual's health over time, helping to track their
progress.
Dr Jenny Brockis, an independent brain health and workplace
performance consultant said: "The objective mood and cognition
assessments are sensitive to the potential presence of an
underlying mental health condition, facilitating early intervention
before productivity and performance are impacted. The result is not
only good for a company's bottom line, it promotes a workplace
culture of care that has the potential of reducing the costs of
absenteeism, presenteeism and high staff turnover."
Dr Steven Powell, Chief Executive Officer, Cambridge Cognition
said: "We are delighted to announce this important digital health
product, building on the success of our gold standard technologies
used in over one million clinical trial assessments. CANTAB
BrainHealth(TM) software will be licensed globally to occupational
health providers and channel partners, offering an urgent solution
for employers and enabling their employees to thrive."
Sources:
(1) World Health Organization (WHO) March 30, 2017
(2) World Federation for Mental Health. WMHD Mental Health in
the Workplace Report 2017
Enquiries
Cambridge Cognition Holdings PLC
Steven Powell, Chief Executive Officer Tel: 01223 810 700
Noah Konig, Director of Marketing press@camcog.com
finnCap Ltd (NOMAD and Joint Broker) Tel: 020 7220 0500
Geoff Nash / Simon Hicks (Corporate Finance)
Alice Lane (Corporate Broking)
Dowgate Capital Stockbrokers Limited (Joint Tel: 020 3903 7715
Broker)
David Poutney / James Serjeant
IFC Advisory Ltd (Financial PR and IR) Tel: 020 3934 6630
Graham Herring / Miles Nolan / Zach Cohen
About Cambridge Cognition
Cambridge Cognition is a digital neuroscience company developing
software products to better understand, detect and treat brain
health conditions. The company's cognitive technologies are used to
accelerate the research and development of new treatments, enhance
understanding of the brain and accurately assess cognitive health
in patients worldwide.
For further information visit www.cambridgecognition.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEKLFFVQFXBBB
(END) Dow Jones Newswires
June 20, 2018 02:00 ET (06:00 GMT)
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From Apr 2024 to May 2024
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From May 2023 to May 2024